Cannabis Bioscience International Holdings, Inc. CBIH
Services-Commercial Physical & Biological Research · CIK 0001411057 · Fiscal year ends 0531
Revenue
$11.20K
Fiscal year ended 2026-02-28Operating income
-$93.26K
Fiscal year ended 2026-02-28Free cash flow
—Unavailable
Fiscal year ended 2026-02-28Cannabis Bioscience International Holdings, Inc. (CBIH) reported revenue of $11.20K and net income of -$103.93K for the fiscal year ended 2026-02-28. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Cannabis Bioscience International Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.
Income
Cannabis Bioscience International Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 |
|---|
| Revenue | $11.20K | $53.27K | $24.20K | $34.96K | $14.93K | $74.25K | $178.89K | $75.86K | $36.41K | $63.75K |
|---|
| Cost of revenue | $3.04K | $10.50K | $8.14K | $4.54K | $19.40K | $7.80K | $8.36K | $9.88K | $11.81K | $15.09K |
|---|
| Gross profit | $8.16K | $42.77K | $16.06K | $30.41K | -$4.46K | $66.44K | $170.52K | $65.98K | $24.60K | $48.66K |
|---|
| Operating income | -$93.26K | -$95.88K | -$74.78K | -$134.90K | -$129.23K | -$59.63K | -$97.60K | -$29.63K | -$159.97K | -$94.51K |
|---|
| Net income | -$103.93K | -$116.97K | -$82.64K | -$211.74K | -$181.24K | -$79.53K | -$76.30K | -$135.94K | -$209.19K | -$124.43K |
|---|
| Research & development | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Weighted-average diluted shares | shares 11.63B | shares 11.63B | shares 11.63B | —Unavailable | shares 10.73B | shares 10.50B | shares 10.46B | —Unavailable | shares 10.37B | shares 10.33B |
|---|
| Pretax income | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Income tax expense | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Diluted EPS | $-0.00 | $-0.00 | $-0.00 | —Unavailable | $-0.00 | $-0.00 | $-0.00 | —Unavailable | $-0.00 | $-0.00 |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| General & administrative | $26.83K | $30.97K | $23.31K | -$49.69K | $50.17K | $40.13K | $61.30K | $9.75K | $25.29K | $8.41K |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
Cannabis Bioscience International Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 |
|---|
| Cash & equivalents | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Total assets | $1.54K | $22.13K | $18.94K | $31.88K | $14.89K | —Unavailable | $46.28K | $57.16K | $93.97K | $101.84K |
|---|
| Current assets | $1.54K | $22.13K | $18.94K | $29.08K | $3.79K | —Unavailable | $18.74K | $21.49K | $18.43K | $19.74K |
|---|
| Total liabilities | $1.47M | $1.39M | $1.27M | $1.20M | $1.24M | —Unavailable | $1.10M | $1.14M | $1.07M | $943.73K |
|---|
| Current liabilities | $1.22M | $1.14M | $1.02M | $945.96K | $970.06K | —Unavailable | $852.10K | $881.91K | $801.05K | $660.31K |
|---|
| Total equity incl. NCI | -$1.47M | -$1.36M | -$1.25M | -$1.16M | -$1.23M | -$1.13M | -$1.06M | -$1.08M | -$976.08K | -$841.89K |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | $1.27K | $21.81K | $8.97K | $6.38K | $2.64K | —Unavailable | $17.18K | $20.14K | $17.04K | $19.40K |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | $249.50K | $249.50K | $249.50K | $249.50K | $249.50K | —Unavailable | $249.50K | $249.36K | $249.50K | $249.50K |
|---|
| Accounts payable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Cash flow
Cannabis Bioscience International Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 |
|---|
| Operating cash flow | -$14.60K | -$5.49K | -$103.71K | -$144.31K | -$82.81K | -$72.09K | -$30.41K | -$174.44K | -$9.08K | -$221.25K |
|---|
| Capital expenditures | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Investing cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Financing cash flow | —Unavailable | —Unavailable | —Unavailable | $156.72K | —Unavailable | —Unavailable | $30.63K | $174.40K | $9.53K | $216.84K |
|---|
| Net change in cash | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $457 | —Unavailable |
|---|
| Stock-based compensation | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Derived
Cannabis Bioscience International Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 |
|---|
| Free cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross margin | 72.8% | 80.3% | 66.4% | 87.0% | -29.9% | 89.5% | 95.3% | 87.0% | 67.6% | 76.3% |
|---|
| Operating margin | -832.3% | -180.0% | -309.0% | -385.9% | -865.5% | -80.3% | -54.6% | -39.1% | -439.3% | -148.3% |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | 0.00x | 0.02x | 0.02x | 0.03x | 0.00x | —Unavailable | 0.02x | 0.02x | 0.02x | 0.03x |
|---|
| Revenue YoY growth | -25.0% | -28.3% | -86.5% | -53.9% | -59.0% | 16.5% | 145.7% | 63.5% | -29.0% | -22.8% |
|---|
| Net margin | -927.6% | —Unavailable | —Unavailable | -605.7% | -1213.9% | —Unavailable | —Unavailable | -179.2% | -574.5% | —Unavailable |
|---|
| R&D / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CBIH in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.